Asthma, Aspirin-Induced Clinical Trial
Official title:
A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory drugs.
This is a randomized, placebo-controlled, double-blind phase 2 trial evaluating approximately 76 subjects with symptomatic AERD on the safety and efficacy of 8 weeks of oral ifetroban treatment. Eligible AERD subjects will be randomized to receive 8 weeks of either oral ifetroban daily or matching placebo followed by a 2-week post-treatment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT01681615 -
Challenge Test for Acetylsalicylic Acid Hypersensitivity
|
N/A | |
| Terminated |
NCT01320072 -
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
|
||
| Completed |
NCT01867281 -
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases
|
Phase 4 | |
| Completed |
NCT02824523 -
Role of Inflammatory Mediators in AERD
|
||
| Completed |
NCT01597375 -
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
|
Phase 2 | |
| Recruiting |
NCT04823585 -
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
|
N/A | |
| Recruiting |
NCT05575037 -
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
|
Phase 2 | |
| Completed |
NCT03326063 -
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
|
Phase 2 |